ASCIA Newsletter October 2016

This email contains pictures, if you don’t see them, view it online
 
ASCIA Update aims to provide current information to the community about allergic diseases, immunodeficiencies and other immune diseases.
 
  ASCIA UPDATE - October 2016  
 
 
 

ASCIA Update aims to provide current information to the community about allergic diseases, immunodeficiencies and other immune diseases.

 
 
--
 

KABAM – Allergy survey for teens and young adults

KABAM-survey600

The National Allergy Strategy Knowledge and Barriers to Allergy Management (KABAM) survey for teens and young adults is now available online up until 3 November 2016. This survey is for people aged 12-24 years old with severe allergy.

The survey is being conducted to enable us to collect information about what 12-24 year olds with severe allergy would like to know about managing their allergy and how they would like to access the information.

As the survey will guide resource development it is important the survey is completed by the individual not their parent or guardian.

For further information www.nationalallergystrategy.org.au/kabam-survey  

 
 

ASCIA 2016 AGM and Conference Reports 

ASCIA2016AR

The ASCIA Annual Report 2016 includes reports that were presented at the Annual General Meeting on 15 September 2016. The Annual Report is available at www.allergy.org.au/members/ascia-annual-reports

If you missed the last issue of this newsletter you can read about the ASCIA 2016 conference on the ASCIA website: www.allergy.org.au/conferences/ascia-annual-conference#s2016

Preparations are now well underway for the ASCIA 2017 Conference in Auckland, New Zealand from 12-15 September 2017 at the Viaduct Events Centre.

The organising committee comprises Dr Anthony Jordan (co-chair), Dr Maia Brewerton (co-chair), Dr Andy Baker and Dr Jan Sinclair. Confirmed international speakers include Professor Carsten Bindslev-Jensen, Professor Jonathan Hourihane, Professor Werner Pichler, Professor Jennifer Puck and Dr Lene Heise Garvey. 

 
 

Berinert now funded by NBA for HAE   

Berinert (supplied by CSL Behring) is now funded by the National Blood Authority (NBA) for use in patients in Australia with Type I and II HAE for the:

  • treatment of acute attacks
  • pre-procedural (short term) prophylaxis for high risk procedures such as dental work, head or neck surgery, or surgery requiring intubation
  • second line as routine (long term) prophylaxis for patients who experience the equivalent of eight or more acute attacks per month.

The announcement is available on the NBA website www.blood.gov.au/plasma-and-recombinant-product-procurement    

 
 

Everyone has a story

Dorotea

Earlier this year we shared the story of Dorotea and her journey with FPIES and the response was wonderful!

Are you interested in sharing your story about allergy or immune disease to help others and raise awareness?

Do you know of someone who would be willing to describe their journey with these diseases?

If so, we'd love to hear from you. Get in touch by email at foundation@allergy.org.au  

You can read about Dorotea at www.allergyimmunology.org.au/news/70-dorotea-s-story

 
---
 
 
ASCIAThe mission of ASCIA is to advance the science and practice of allergy and clinical immunology, by promoting the highest standard of medical practice, training, education and research, to improve the health and quality of life of people with allergic diseases, immunodeficiencies and other immune diseases.
 
 
 
AIFAAIFA is dedicated to improving the health of people with allergy and other immune diseases by funding medical research and raising awareness. 
Donate here…
 
     
 
 
twitterfacebookwww.allergy.org.au | contact us
Prefer not to receive our news anymore unsubscribe.